<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="94172">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02011555</url>
  </required_header>
  <id_info>
    <org_study_id>SMRU1304</org_study_id>
    <nct_id>NCT02011555</nct_id>
  </id_info>
  <brief_title>Study of the Effect of a Low Single-dose of Primaquine Against Malaria</brief_title>
  <official_title>Phase 2a Dose Escalation Study of the Efficacy, Safety and Pharmacokinetics of Low Single-dose Primaquine Combined With DHA-piperaquine for Gametocytocidal Activity Against P.Falciparum</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Oxford</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Malaria Research and Training Centre, Bamako, Mali</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Oxford</source>
  <oversight_info>
    <authority>Thailand: Ethical Committee</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Since the 1950s, it has been known that lower doses of primaquine can be highly effective at
      reducing gametocyte carriage and infectivity to mosquitoes. Evidence suggests that doses as
      low as 0.1 mg/kg could be effective and low dose primaquine is likely to have an improved
      safety profile, especially on those with G6PD deficiency.

      The first step is to identify the lowest efficacious dose in those with the lowest safety
      risk. This investigation has just been recommended as having the highest priority by the
      World Health Organisation Global Malaria Programme Malaria Policy Advisory Committee.  Thus,
      we plan a dose escalation study to identify the lowest efficacious dose in malaria infected
      G6PD normal adults which can prevent transmission in mosquitoes.

      In addition, we will also carry out a feeding experiment.  A. dirus mosquitoes will be fed
      on P.falciparum infected blood meal through a membrane feed before and after administration
      of primaquine at -0.5, 0, and 24 hours and after 2 and 7 days. Infectivity to mosquitoes
      will be measured by the presence of oocysts and sporozoites respectively at 7-9 and 14-16
      days post infected blood meal.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase 2a dose escalation study. The study design is adaptive, meaning that earlier
      doses of drug tested will inform on whether a subsequent group is needed.The study will be
      conducted sequentially:

        1. Adult G6PD-normal malaria patients will be enrolled and treated with Dihydroartemisinin
           - Piperaquine (DP) and increasing doses of primaquine (PQ). The effect on gametocytes
           will be measured. Blood samples for membrane feeding experiments will be collected. The
           safety of study participants, specifically signs of hemolysis will be closely followed.

        2. Blood from study participants will be used in membrane feeding experiments. The
           primaquine doses will be increased until no oocysts can be detected in membrane feeding
           experiments.

      The intervention will be a dose escalation study in groups of 10 G6PD-normal participants.
      They will each receive between 0 and 0.5mg/kg. A control group will receive DP without
      primaquine.

      The first 10 participants will be randomly allocated to each treatment groups 1, 3, and 5
      (30 participants in total). Due to the adaptive design, subsequent groups will not be
      randomized. Once the membrane feeding experiments as well as the 28 follow-up have been
      completed the findings will be reviewed by the investigators. If there is evidence that
      mosquitoes have become infected the next higher primaquine dose will be administered to the
      next group (10 study participants). The DSMC will review the results and decide either to
      proceed or not to the next group. We will follow the dosing groups outlined below:

        -  first group (total number 10) : Will be treated with dihydroartemisinin-piperaquine
           (DP) and will not get primaquine(PQ),

        -  Second group (total number 10): Will be treated with dihydroartemisinin-piperaquine
           (DP) and very low dose of (0.125 mg/kg) primaquine(PQ)

        -  Third group (total number 10): Will be treated with dihydroartemisinin-piperaquine (DP)
           and low dose of (0.5 mg/kg) primaquine(PQ)

      After this, the study drug will be given with next higher PQ dose:

        -  Fourth group (total number 10): Will be treated with dihydroartemisinin-piperaquine
           (DP) and dose of 0.0625/kg primaquine(PQ)

        -  Fifth group (total number 10): Will be treated with dihydroartemisinin-piperaquine (DP)
           and a dose of 0.25mg/kg primaquine(PQ)

        -  Sixth group (total number 10): Will be treated with dihydroartemisinin-piperaquine (DP)
           and a dose of primaquine(PQ) (which we will know after we have the result of PQ highest
           group)

      Doses will be given on the first day of treatment.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Anticipated">January 2015</completion_date>
  <primary_completion_date type="Anticipated">January 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Mosquito infectivity</measure>
    <time_frame>Day 7</time_frame>
    <safety_issue>No</safety_issue>
    <description>The primary outcome measure will be mosquito infectivity assessed through membrane feeding and measured by oocyst prevalence in mosquitoes dissected on day 7 post feed</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>asexual parasite and gametocyte density rate</measure>
    <time_frame>Day 0,1,2,3,7,14 and 28</time_frame>
    <safety_issue>No</safety_issue>
    <description>asexual parasite and gametocyte density determined microscopically and by molecular methods on day 0,1,2,3,7,14 and 28</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics relationships for primaquine</measure>
    <time_frame>Day 0 and Day 1</time_frame>
    <safety_issue>No</safety_issue>
    <description>Participant will be collected whole blood 1.0 ml for pharmacokinetic measurement in appropriate collection tubes containing sodium or lithium heparin as the anticoagulant at 0, 1, 2, 3, 4, 6, 8, 12 and 24 hrs.
Measure half-life, Cmax, AUC, Tmax of primaquine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>safety assessment</measure>
    <time_frame>Day 0,1,2,3,7,14  and 28</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Safety assesment will be measured by sign of hemolysis such as hemoglobinuria and hemoglobin will be conducted on day 0,1,2,3,7,14  and 28</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Malaria</condition>
  <arm_group>
    <arm_group_label>Dihydroartemisinin - Piperaquine (DP)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>DP will be given for 3 day and the dose will receive depend on the body weight</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Primaquine 0.0625 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Primaquine 0.0625 mg/kg will be given single dose on Day 0 with DP</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Primaquine 0.125 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Primaquine 0.125 mg/kg will be given single dose on day 0 with DP</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Primaquine 0.25 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Primaquine 0.25 mg/kg will be given single dose on day 0 with DP</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Primaquine 0.5 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Primaquine 0.5 mg/kg will be given single on day 0 with DP</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Primaquine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The dose of Primaquine will be decided depend on previous findings and will be given on the first day of treatment with DP</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dihydroartemisinin - Piperaquine (DP)</intervention_name>
    <description>DP will be given over three days and the dose will be depended on the body weight.</description>
    <arm_group_label>Dihydroartemisinin - Piperaquine (DP)</arm_group_label>
    <arm_group_label>Primaquine 0.0625 mg/kg</arm_group_label>
    <arm_group_label>Primaquine 0.125 mg/kg</arm_group_label>
    <arm_group_label>Primaquine 0.25 mg/kg</arm_group_label>
    <arm_group_label>Primaquine 0.5 mg/kg</arm_group_label>
    <arm_group_label>Primaquine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Primaquine (PQ)</intervention_name>
    <description>Primaquine doses will vary by group. Trial participants will be given standard dose of DP over three days + single dose PQ on Day 0.</description>
    <arm_group_label>Primaquine 0.0625 mg/kg</arm_group_label>
    <arm_group_label>Primaquine 0.125 mg/kg</arm_group_label>
    <arm_group_label>Primaquine 0.25 mg/kg</arm_group_label>
    <arm_group_label>Primaquine 0.5 mg/kg</arm_group_label>
    <arm_group_label>Primaquine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male

          2. Age range of 18 to 50 years

          3. Uncomplicated malaria diagnosed by:

          4. Malaria blood thick film positive

          5. A history of fever

          6. Presence of gametocytes on thick blood film

          7. Agrees to admission to study ward for 26 hours post diagnosis and available for
             follow up visits

          8. No allergies to study drugs

          9. Hemoglobin &gt;= 8 g/dL or Hematocrit  â‰¥  25%

         10. Written, informed consent

        Exclusion Criteria:

          1. Female

          2. Under the age of 18 years or older than 50 years

          3. Blood thick film negative for sexual stages of malaria

          4. Previous reaction to study drugs/ known allergy to study drugs

          5. Consent not given

          6. Does not agree to follow up procedures

          7. G6PD phenotypically deficient

          8. Hemoglobin &lt; 8 g/dL or haematocrit&lt; 25%

          9. Previously received other antimalarial drug(s)
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Francois Nosten, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shoklo Malaria Research Unit</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chiara Andolina, BA, MSc</last_name>
    <email>chiara@tropmedres.ac</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Phaik Yeong Cheah, PhD</last_name>
    <email>phaikyeong@tropmedres.ac</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Shoklo Malaria Research Unit</name>
      <address>
        <city>Mae Sot</city>
        <state>Tak</state>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Chiara Andolina, BA,MSc</last_name>
      <email>chiara@tropmedres.ac</email>
    </contact>
    <investigator>
      <last_name>Aung PyaePhyo, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Cindy Chu, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chiara Andolina, BA,MSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 6, 2014</lastchanged_date>
  <firstreceived_date>November 29, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>mosquitoes infected</keyword>
  <keyword>Primaquine escalation</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Malaria</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Primaquine</mesh_term>
    <mesh_term>Dihydroquinghaosu</mesh_term>
    <mesh_term>Artemisinins</mesh_term>
    <mesh_term>Piperaquine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
